Roivant Sciences Q4 EPS $(0.20) Beats $(0.36) Estimate, Sales $27.38M Beat $21.53M Estimate
Portfolio Pulse from Benzinga Newsdesk
Roivant Sciences (NASDAQ:ROIV) reported Q4 losses of $(0.20) per share, beating the analyst consensus estimate of $(0.36) by 44.44%. The company also reported quarterly sales of $27.38 million, surpassing the analyst consensus estimate of $21.53 million by 27.15%. This represents a 196.82% increase over sales from the same period last year.
June 28, 2023 | 11:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roivant Sciences reported better than expected Q4 results, with both EPS and sales beating estimates. This could lead to a positive market reaction.
Roivant Sciences reported Q4 results that exceeded analyst estimates, which is typically a positive signal for the market. The significant increase in sales compared to the same period last year also indicates strong growth, which could further boost investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100